tetano
Editor, Senior Moderator
Sci Immunol
. 2023 Jan 26;eade0958.
doi: 10.1126/sciimmunol.ade0958. Online ahead of print.
Human neutralizing antibodies to cold linear epitopes and subdomain 1 of the SARS-CoV-2 spike glycoprotein
Filippo Bianchini[SUP] 1 [/SUP], Virginia Crivelli[SUP] 1 [/SUP], Morgan E Abernathy[SUP] 2 [/SUP], Concetta Guerra[SUP] 1 [/SUP], Martin Palus[SUP] 3 4 [/SUP], Jonathan Muri[SUP] 1 [/SUP], Harold Marcotte[SUP] 5 [/SUP], Antonio Piralla[SUP] 6 [/SUP], Mattia Pedotti[SUP] 1 [/SUP], Raoul De Gasparo[SUP] 1 [/SUP], Luca Simonelli[SUP] 1 [/SUP], Milos Matkovic[SUP] 1 [/SUP], Chiara Toscano[SUP] 1 [/SUP], Maira Biggiogero[SUP] 7 [/SUP], Veronica Calvaruso[SUP] 7 [/SUP], Pavel Svoboda[SUP] 3 4 8 9 [/SUP], Tomás Cervantes Rincón[SUP] 1 [/SUP], Tommaso Fava[SUP] 1 [/SUP], Lucie Podešvová[SUP] 1 [/SUP], Akanksha A Shanbhag[SUP] 1 [/SUP], Andrea Celoria[SUP] 1 [/SUP], Jacopo Sgrignani[SUP] 1 [/SUP], Michal Stefanik[SUP] 4 10 [/SUP], Vaclav Hönig[SUP] 3 4 [/SUP], Veronika Pranclova[SUP] 3 11 [/SUP], Tereza Michalcikova[SUP] 12 [/SUP], Jan Prochazka[SUP] 12 [/SUP], Giuditta Guerrini[SUP] 13 [/SUP], Dora Mehn[SUP] 13 [/SUP], Annalisa Ciabattini[SUP] 14 [/SUP], Hassan Abolhassani[SUP] 5 15 [/SUP], David Jarrossay[SUP] 1 [/SUP], Mariagrazia Uguccioni[SUP] 1 [/SUP], Donata Medaglini[SUP] 14 [/SUP], Qiang Pan-Hammarström[SUP] 5 [/SUP], Luigi Calzolai[SUP] 13 [/SUP], Daniel Fernandez[SUP] 16 [/SUP], Fausto Baldanti[SUP] 6 17 [/SUP], Alessandra Franzetti-Pellanda[SUP] 7 [/SUP], Christian Garzoni[SUP] 18 [/SUP], Radislav Sedlacek[SUP] 12 [/SUP], Daniel Ruzek[SUP] 3 4 8 [/SUP], Luca Varani[SUP] 1 [/SUP], Andrea Cavalli[SUP] 1 19 [/SUP], Christopher O Barnes[SUP] 2 20 [/SUP], Davide F Robbiani[SUP] 1 [/SUP]
Affiliations
Abstract
Emergence of SARS-CoV-2 variants diminishes the efficacy of vaccines and antiviral monoclonal antibodies. Continued development of immunotherapies and vaccine immunogens resilient to viral evolution is therefore necessary. Using coldspot-guided antibody discovery, a screening approach that focuses on portions of the virus spike glycoprotein that are both functionally relevant and averse to change, we identified human neutralizing antibodies to highly conserved viral epitopes. Antibody fp.006 binds the fusion peptide and cross-reacts against coronaviruses of the four genera, including the nine human coronaviruses, through recognition of a conserved motif that includes the S2´ site of proteolytic cleavage. Antibody hr2.016 targets the stem helix and neutralizes SARS-CoV-2 variants. Antibody sd1.040 binds to subdomain 1, synergizes with antibody rbd.042 for neutralization and, like fp.006 and hr2.016, protects mice expressing human ACE2 against infection when present as bispecific antibody. Thus, coldspot-guided antibody discovery reveals donor-derived neutralizing antibodies that are cross-reactive with Orthocoronavirinae, including SARS-CoV-2 variants.
. 2023 Jan 26;eade0958.
doi: 10.1126/sciimmunol.ade0958. Online ahead of print.
Human neutralizing antibodies to cold linear epitopes and subdomain 1 of the SARS-CoV-2 spike glycoprotein
Filippo Bianchini[SUP] 1 [/SUP], Virginia Crivelli[SUP] 1 [/SUP], Morgan E Abernathy[SUP] 2 [/SUP], Concetta Guerra[SUP] 1 [/SUP], Martin Palus[SUP] 3 4 [/SUP], Jonathan Muri[SUP] 1 [/SUP], Harold Marcotte[SUP] 5 [/SUP], Antonio Piralla[SUP] 6 [/SUP], Mattia Pedotti[SUP] 1 [/SUP], Raoul De Gasparo[SUP] 1 [/SUP], Luca Simonelli[SUP] 1 [/SUP], Milos Matkovic[SUP] 1 [/SUP], Chiara Toscano[SUP] 1 [/SUP], Maira Biggiogero[SUP] 7 [/SUP], Veronica Calvaruso[SUP] 7 [/SUP], Pavel Svoboda[SUP] 3 4 8 9 [/SUP], Tomás Cervantes Rincón[SUP] 1 [/SUP], Tommaso Fava[SUP] 1 [/SUP], Lucie Podešvová[SUP] 1 [/SUP], Akanksha A Shanbhag[SUP] 1 [/SUP], Andrea Celoria[SUP] 1 [/SUP], Jacopo Sgrignani[SUP] 1 [/SUP], Michal Stefanik[SUP] 4 10 [/SUP], Vaclav Hönig[SUP] 3 4 [/SUP], Veronika Pranclova[SUP] 3 11 [/SUP], Tereza Michalcikova[SUP] 12 [/SUP], Jan Prochazka[SUP] 12 [/SUP], Giuditta Guerrini[SUP] 13 [/SUP], Dora Mehn[SUP] 13 [/SUP], Annalisa Ciabattini[SUP] 14 [/SUP], Hassan Abolhassani[SUP] 5 15 [/SUP], David Jarrossay[SUP] 1 [/SUP], Mariagrazia Uguccioni[SUP] 1 [/SUP], Donata Medaglini[SUP] 14 [/SUP], Qiang Pan-Hammarström[SUP] 5 [/SUP], Luigi Calzolai[SUP] 13 [/SUP], Daniel Fernandez[SUP] 16 [/SUP], Fausto Baldanti[SUP] 6 17 [/SUP], Alessandra Franzetti-Pellanda[SUP] 7 [/SUP], Christian Garzoni[SUP] 18 [/SUP], Radislav Sedlacek[SUP] 12 [/SUP], Daniel Ruzek[SUP] 3 4 8 [/SUP], Luca Varani[SUP] 1 [/SUP], Andrea Cavalli[SUP] 1 19 [/SUP], Christopher O Barnes[SUP] 2 20 [/SUP], Davide F Robbiani[SUP] 1 [/SUP]
Affiliations
- PMID: 36701425
- DOI: 10.1126/sciimmunol.ade0958
Abstract
Emergence of SARS-CoV-2 variants diminishes the efficacy of vaccines and antiviral monoclonal antibodies. Continued development of immunotherapies and vaccine immunogens resilient to viral evolution is therefore necessary. Using coldspot-guided antibody discovery, a screening approach that focuses on portions of the virus spike glycoprotein that are both functionally relevant and averse to change, we identified human neutralizing antibodies to highly conserved viral epitopes. Antibody fp.006 binds the fusion peptide and cross-reacts against coronaviruses of the four genera, including the nine human coronaviruses, through recognition of a conserved motif that includes the S2´ site of proteolytic cleavage. Antibody hr2.016 targets the stem helix and neutralizes SARS-CoV-2 variants. Antibody sd1.040 binds to subdomain 1, synergizes with antibody rbd.042 for neutralization and, like fp.006 and hr2.016, protects mice expressing human ACE2 against infection when present as bispecific antibody. Thus, coldspot-guided antibody discovery reveals donor-derived neutralizing antibodies that are cross-reactive with Orthocoronavirinae, including SARS-CoV-2 variants.